Axonics Modulation Technologies (NASDAQ:AXNX) announces FDA approval of second-generation Programmer for its r-SNM System under a premarket approval (“PMA”) application supplement.
The new Programmer is used to program the Axonics external trial neurostimulator as well as the implantable neurostimulator in both the procedure and post-operative environments.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.